Robert Tjin Tham Sjin
YOU?
Author Swipe
View article: Figure S1 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Figure S1 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Figure S1. MAGeCK analysis of CRISPR screens – related to Figure 1. A) Volcano plots showing MAGeCK analysis of CRISPR-Cas9 screens performed in BRCA1 wildtype cancer cell lines, A549 (left) and CAL27 (right). Genes on the le…
View article: Table S3 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Table S3 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Table S3
View article: Figure S4 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Figure S4 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Figure S4. Impact on DNA replication, cell cycle, and apoptosis with PARP inhibitor treatment in BRCA2 wildtype and mutant cells – related to Figure 5. A) Graph showing quantification of % EdU-positive ‘S’ phase cells. DLD-1 …
View article: Table S1 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Table S1 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Table S1
View article: Table S2 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Table S2 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Table S2
View article: Supplementary Data from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Supplementary Data from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Materials
View article: Data from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Data from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
PARP inhibitors (PARPi) are an approved class of anticancer therapeutics that inhibit the activities of PARP1/2 and produce synthetic lethality in BRCA1/2-mutated cancers because of the absence of a functional homologous recombinati…
View article: Figure S2 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Figure S2 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Figure S2. POLB knockout alone does not induce synthetic lethality in cancer cell lines across multiple lineages - related to Figure 2. Viability is not impacted in POLB knockout cells as evidenced by the DepMap Public (Q1 20…
View article: Figure S3 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Figure S3 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Figure S3. Viability with niraparib and olaparib in additional clones – related to Figure 2. A) Immunoblotting analysis of POLB from 2 individual clones confirming POLB knockout in BRCA1 mutant MDA-MB-436 (left) and SUM149PT …
View article: Figure S5 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors
Figure S5 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors Open
Supplementary Figure S5. Body weight of the animals is not impacted by the treatment with niraparib – related to Figure 6. A) Effect on body weights of animals containing MDA-MB-436 sgIntron or sgPOLB xenografts treated with vehicle and ni…
View article: Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 7 - PDF file 352K, H&E and immunohistochemical (Ki67) staining of tumors derived from EGFR mutant GEM models
View article: Supplementary Table 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Table 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Table 1 - PDF file 114K, Kinase selectivity profiling of CO-1686
View article: Supplementary Table 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Table 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Table 2 - PDF file 113K, Mutant EGFR cell panel profiling of CO-1686
View article: Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 9 - PDF file 168K, NCI-H1975 parental and CO-1686 resistant clones cluster into distinct groups using an RNA-based EMT signature
View article: Data from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Data from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Patients with non–small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resis…
View article: Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing Open
PDF - 252K, Supplemental Table 1. Mass spectrometry on EGFR-L858R/T790M protein. Supplemental Table 2. EGFR modulation in A431, H1975 and HCC827 cells by compound 3. Supplemental Table 3. Kinase selectivity profile of compound 3, afatinib …
View article: Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 8 - PDF file 215K, Photomicrographs of CO-1686 resistant NCI-H1975 cell (COR) clones and quantification of EGFR siRNA knockdown in COR clones
View article: Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 11 - PDF file 255K, Analysis of the role of AXL in mediating CO-1686 resistance in COR cell clones.
View article: Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
Supplementary Tables 1 through 4 and Supplementary Figures 1 through 5 from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing Open
PDF - 252K, Supplemental Table 1. Mass spectrometry on EGFR-L858R/T790M protein. Supplemental Table 2. EGFR modulation in A431, H1975 and HCC827 cells by compound 3. Supplemental Table 3. Kinase selectivity profile of compound 3, afatinib …
View article: Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 7 - PDF file 352K, H&E and immunohistochemical (Ki67) staining of tumors derived from EGFR mutant GEM models
View article: Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 5 - PDF file 134K, Schedule dependence of CO-1686 antitumor activity in NCI-H1975 mode
View article: Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 11 - PDF file 255K, Analysis of the role of AXL in mediating CO-1686 resistance in COR cell clones.
View article: Supplementary Materials and Methods from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Materials and Methods from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Materials and Methods - PDF file 179K, Supplemental materials and methods for Walter et al. manuscript
View article: Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 5 - PDF file 134K, Schedule dependence of CO-1686 antitumor activity in NCI-H1975 mode
View article: Data from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
Data from <i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing Open
Patients with non–small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib. However, all patients relapse because of the em…
View article: Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 8 - PDF file 215K, Photomicrographs of CO-1686 resistant NCI-H1975 cell (COR) clones and quantification of EGFR siRNA knockdown in COR clones
View article: Supplementary Figure 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 2 - PDF file 111K, CO-1686 inhibits cell growth in EGFR-mutant erlotinib-resistant cell lines
View article: Supplementary Table 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Table 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Table 3 - PDF file 119K, Comparison of differentially expressed genes in COR cell lines with the EMT signature of Byers et al. (2013)
View article: Supplementary Table 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Table 2 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Table 2 - PDF file 113K, Mutant EGFR cell panel profiling of CO-1686
View article: Supplementary Figure 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Supplementary Figure 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Open
Supplementary Figure 1 - PDF file 596K, Covalent binding of the EGFR L858R/T790M protein by CO-1686